Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s EVM401 Series represents a growing class of psychedelic-inspired therapies designed to provide the benefits of traditional psychedelics without the hallucinogenic effects that can limit their clinical use.

The United States Patent and Trademark Office issued Patent No. 12,195,439 to Enveric on January 14, 2025, marking a milestone for the Cambridge, Massachusetts-based biotechnology company. Entitled “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives,” the patent covers compounds derived from mescaline that have been specifically engineered to target key brain receptors associated with various mental health conditions.

These compounds aren’t your traditional psychedelics. While they draw inspiration from the chemical structure of mescaline, they’ve been carefully modified to retain therapeutic potential while eliminating hallucinogenic effects. This approach could make them more accessible for patients and easier to integrate into standard medical practice.

“With the issuance of this patent, we are not only protecting our innovations but also paving the way for the next generation of neuropsychiatric treatments that move beyond traditional approaches,” said Dr. Joseph Tucker, CEO of Enveric Biosciences.

What makes the EVM401 Series particularly noteworthy is its unique mechanism of action. Preliminary testing reveals these compounds interact with multiple critical neurological receptors:

This multi-target approach could potentially address several challenging conditions that have limited treatment options today, including addiction, ADHD, and anxiety disorders.

While the patent strengthens Enveric’s intellectual property portfolio, the company remains focused on its lead drug candidate, EB-003, which is being prepared for clinical trials. However, the EVM401 Series represents an important expansion of its therapeutic pipeline.

“Our strategic focus remains on advancing EB-003 toward clinical trials, but the EVM401 Series reflects our broader vision—building a robust portfolio of differentiated, next-generation therapeutics,” Dr. Tucker explained.

Enveric’s approach leverages its proprietary Psybrary™ platform, which houses information on the development and use of both existing and novel molecules for specific mental health indications. This resource allows the company to create a robust intellectual property portfolio of drug candidates with unique therapeutic profiles.

The patent comes at a time when interest in psychedelic medicine is growing rapidly, but many potential treatments face regulatory and practical challenges due to their hallucinogenic properties. By developing compounds that retain therapeutic benefits without psychoactive effects, Enveric may offer a path forward that is more compatible with conventional medical practices.

This approach could be particularly valuable given the escalating mental health crisis worldwide and the limitations of existing treatments. Current medications for conditions like addiction and ADHD often come with significant side effects or limited efficacy for many patients.

The non-hallucinogenic nature of these compounds may also address concerns about abuse potential that have slowed the adoption of some psychedelic-inspired treatments. For patients who cannot tolerate or do not wish to experience hallucinogenic effects, these compounds could provide a welcome alternative.

Despite the promising nature of this patent, significant work remains before these compounds might reach patients. The pharmaceutical development process is lengthy and expensive, requiring extensive preclinical and clinical testing to demonstrate safety and efficacy.

Enveric’s path forward will likely involve continued preclinical development of the EVM401 Series while advancing its lead candidate EB-003 into human trials. This dual approach allows the company to build long-term value while pursuing near-term clinical milestones.

“This patent is just the beginning,” Dr. Tucker noted. “As we continue to refine and develop the EVM401 Series, we remain committed to delivering safe, effective, and scalable solutions for patients who need them most.”

The announcement comes as the broader psychedelic medicine sector continues to evolve, with several companies pursuing novel approaches to mental health treatment. Enveric’s focus on non-hallucinogenic compounds positions it in a potentially advantageous space between conventional pharmaceuticals and traditional psychedelics.

For investors and industry observers, the patent issuance signals Enveric’s commitment to building a diverse portfolio of intellectual property in the neuropsychiatric space. The company’s stock saw movement following the announcement, reflecting market interest in this emerging therapeutic area.

Perhaps most importantly, Enveric’s EVM401 Series addresses significant unmet needs in psychiatry. Conditions like addiction and treatment-resistant anxiety continue to challenge clinicians and patients alike, with current therapies often providing incomplete relief.

By targeting multiple receptors simultaneously and avoiding hallucinogenic effects, these compounds could potentially offer new options for patients who have not responded to conventional treatments. The ability to modulate both adrenergic and serotonergic systems, along with dopamine transport, provides a novel therapeutic approach that differs from existing medications.

As mental health disorders continue to rise globally, innovations like the EVM401 Series may represent an important step toward more effective treatment options. While much work remains to be done, Enveric’s patent secures its position in what could become a significant new chapter in psychiatric medicine.